Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai 980-8574, Japan.
Division of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai 980-8573, Japan.
Int J Environ Res Public Health. 2022 Jun 28;19(13):7933. doi: 10.3390/ijerph19137933.
Inflammatory bowel disease (IBD) diagnoses are increasing in Japan. Some patients have symptoms that are difficult to control, and further research on IBD is needed. Claims databases, which have a large sample size, can be useful for IBD research. However, it is unclear whether the International Classification of Diseases, Tenth Revision (ICD-10) codes alone can correctly identify IBD. We aimed to develop algorithms to identify IBD in claims databases. We used claims data from the Department of Gastroenterology, Tohoku University Hospital from 1 January 2016 to 31 December 2020. We developed 11 algorithms by combining the ICD-10 code, prescription drug, and workup information. We had access to the database which contains all the information for Crohn's disease and ulcerative colitis patients who visited our department, and we used it as the gold standard. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value for each algorithm. We enrolled 19,384 patients, and among them, 1012 IBD patients were identified in the gold standard database. Among 11 algorithms, Algorithm 4 (ICD-10 code and ≥1 prescription drugs) showed a strong performance (PPV, 94.8%; sensitivity, 75.6%). The combination of an ICD-10 code and prescription drugs may be useful for identifying IBD among claims data.
在日本,炎症性肠病(IBD)的诊断数量正在增加。一些患者的症状难以控制,因此需要对 IBD 进行进一步的研究。包含大量样本的理赔数据库可用于 IBD 研究。然而,仅使用国际疾病分类第十版(ICD-10)代码是否能正确识别 IBD 尚不清楚。我们旨在开发一种算法,以便在理赔数据库中识别 IBD。我们使用了 2016 年 1 月 1 日至 2020 年 12 月 31 日期间来自东北大学医院消化内科的理赔数据。我们通过结合 ICD-10 代码、处方药和检查信息开发了 11 种算法。我们可以访问包含所有来我们科室就诊的克罗恩病和溃疡性结肠炎患者信息的数据库,并将其作为金标准。我们为每种算法计算了敏感性、特异性、阳性预测值(PPV)和阴性预测值。我们共纳入了 19384 名患者,其中在金标准数据库中确定了 1012 名 IBD 患者。在 11 种算法中,算法 4(ICD-10 代码和≥1 种处方药)表现出较强的性能(PPV,94.8%;敏感性,75.6%)。ICD-10 代码和处方药的组合可能有助于从理赔数据中识别 IBD。